Hepatocyte-specific HIF-2α deletion improves fatty liver, parenchymal injury, lobular inflammation in NASH ameliorating the disease evolution to fibrosis [155]. This evidence concerns the gene EPAS1 and metabolic dysfunction-associated steatohepatitis.